Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma (2023)

Peer-Reviewed Study · Jung H, Kim SY, et al. · November 8, 2023

Jung H et al., 2023-11-08: The nearest 2023 mouse study located gave fenbendazole 25 mg/kg intraperitoneally on days 0, 3 and 6 to mice bearing EL-4 T-lymphoma tumours, compared with CHOP chemotherapy, in Current Issues in Molecular Biology – not Cancer Research and not at 10-20 mg/kg.

On days 0, 3, and 6, drugs were inoculated intraperitoneally (IP) as follows: vehicle control group (PBS 120 μL + DMSO 20 μL), CHOP-treated group (CHOP 40 mg/kg), and FBZ-treated group (25 mg/kg).

Jung H et al., 2023-11-08: The nearest 2023 mouse study located gave fenbendazole 25 mg/kg intraperitoneally on days 0, 3 and 6 to mice bearing EL-4 T-lymphoma tumours, compared with CHOP chemotherapy, in Current Issues in Molecular Biology – not Cancer Research and not at 10-20 mg/kg. C4 first mouse study. Study type: animal (mouse T-lymphoma EL-4, syngeneic) plus in vitro; N=6-7 mice per group, 3 groups; country South Korea (Jeju National University); dose 25 mg/kg IP on days 0/3/6, sacrificed day 10; in vitro IC50 0.05 μg/mL; funder: not stated in the article; conflicts: not stated; maker: not stated; comparators: vehicle (PBS/DMSO) and CHOP 40 mg/kg. The book's '2023 study in Cancer Research at 10-20 mg/kg' matches no located paper: PubMed esearch for fenbendazole with 10-20 mg/kg in a 2023 Cancer Research article returned nothing, and no AACR Cancer Research article on fenbendazole was found. Recorded as the nearest real 2023 mouse study; the exact book claim is SOURCE NOT FOUND. Study type: animal.